Overview and Perspectives of Antihypertensive Treatment

Alberto Zanchetti

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

An overview of antihypertensive trials shows that, when absolute rather than relative measures of benefit are considered, a large benefit is derived from treating severe hypertension, whereas in mild hypertension the rate of prevented morbid events is relatively small. However, a greater benefit is observed when a mildly elevated diastolic blood pressure is associated with other risk factors. Thus, antihypertensive therapy in the 1990s needs to be regarded as a component, albeit an important one, in a multiple-strategy approach to prevention and reversal of cardiovascular diseases. At a time when many different classes of antihypertensive agents are available, it is reasonable to ask whether some classes are more suitable than others for the treatment of patients with hypertension and concomitant risk factors such as dyslipidaemias and reduced glucose tolerance. It is well known that thiazide diuretics and β-blockers have potentially adverse effects on lipid and glucose metabolism, that calcium antagonists and ACE-inhibitors are lipid neutral and that α-blockers have potentially favourable effects. Although the real impact of some of these changes is unproven, it is possible that one or more of the metabolic side effects of drugs such as diuretics and β-blockers may offset some of the benefits of reduced blood pressure. Extensive testing of antihypertensive drugs with a favourable profile can be foreseen in the 1990s.

Original languageEnglish
Pages (from-to)85-91
Number of pages7
JournalDrugs
Volume40
Issue number4
DOIs
Publication statusPublished - 1990

Fingerprint

Antihypertensive Agents
Blood pressure
Blood Pressure
Hypertension
Sodium Chloride Symporter Inhibitors
Lipids
Glucose
Therapeutics
Dyslipidemias
Lipid Metabolism
Angiotensin-Converting Enzyme Inhibitors
Diuretics
Metabolism
Cardiovascular Diseases
Calcium
Testing

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Toxicology
  • Health, Toxicology and Mutagenesis

Cite this

Overview and Perspectives of Antihypertensive Treatment. / Zanchetti, Alberto.

In: Drugs, Vol. 40, No. 4, 1990, p. 85-91.

Research output: Contribution to journalArticle

Zanchetti, Alberto. / Overview and Perspectives of Antihypertensive Treatment. In: Drugs. 1990 ; Vol. 40, No. 4. pp. 85-91.
@article{38a08746a1b348ad903001163be5453e,
title = "Overview and Perspectives of Antihypertensive Treatment",
abstract = "An overview of antihypertensive trials shows that, when absolute rather than relative measures of benefit are considered, a large benefit is derived from treating severe hypertension, whereas in mild hypertension the rate of prevented morbid events is relatively small. However, a greater benefit is observed when a mildly elevated diastolic blood pressure is associated with other risk factors. Thus, antihypertensive therapy in the 1990s needs to be regarded as a component, albeit an important one, in a multiple-strategy approach to prevention and reversal of cardiovascular diseases. At a time when many different classes of antihypertensive agents are available, it is reasonable to ask whether some classes are more suitable than others for the treatment of patients with hypertension and concomitant risk factors such as dyslipidaemias and reduced glucose tolerance. It is well known that thiazide diuretics and β-blockers have potentially adverse effects on lipid and glucose metabolism, that calcium antagonists and ACE-inhibitors are lipid neutral and that α-blockers have potentially favourable effects. Although the real impact of some of these changes is unproven, it is possible that one or more of the metabolic side effects of drugs such as diuretics and β-blockers may offset some of the benefits of reduced blood pressure. Extensive testing of antihypertensive drugs with a favourable profile can be foreseen in the 1990s.",
author = "Alberto Zanchetti",
year = "1990",
doi = "10.2165/00003495-199000404-00027",
language = "English",
volume = "40",
pages = "85--91",
journal = "Drugs",
issn = "0012-6667",
publisher = "Adis International Ltd",
number = "4",

}

TY - JOUR

T1 - Overview and Perspectives of Antihypertensive Treatment

AU - Zanchetti, Alberto

PY - 1990

Y1 - 1990

N2 - An overview of antihypertensive trials shows that, when absolute rather than relative measures of benefit are considered, a large benefit is derived from treating severe hypertension, whereas in mild hypertension the rate of prevented morbid events is relatively small. However, a greater benefit is observed when a mildly elevated diastolic blood pressure is associated with other risk factors. Thus, antihypertensive therapy in the 1990s needs to be regarded as a component, albeit an important one, in a multiple-strategy approach to prevention and reversal of cardiovascular diseases. At a time when many different classes of antihypertensive agents are available, it is reasonable to ask whether some classes are more suitable than others for the treatment of patients with hypertension and concomitant risk factors such as dyslipidaemias and reduced glucose tolerance. It is well known that thiazide diuretics and β-blockers have potentially adverse effects on lipid and glucose metabolism, that calcium antagonists and ACE-inhibitors are lipid neutral and that α-blockers have potentially favourable effects. Although the real impact of some of these changes is unproven, it is possible that one or more of the metabolic side effects of drugs such as diuretics and β-blockers may offset some of the benefits of reduced blood pressure. Extensive testing of antihypertensive drugs with a favourable profile can be foreseen in the 1990s.

AB - An overview of antihypertensive trials shows that, when absolute rather than relative measures of benefit are considered, a large benefit is derived from treating severe hypertension, whereas in mild hypertension the rate of prevented morbid events is relatively small. However, a greater benefit is observed when a mildly elevated diastolic blood pressure is associated with other risk factors. Thus, antihypertensive therapy in the 1990s needs to be regarded as a component, albeit an important one, in a multiple-strategy approach to prevention and reversal of cardiovascular diseases. At a time when many different classes of antihypertensive agents are available, it is reasonable to ask whether some classes are more suitable than others for the treatment of patients with hypertension and concomitant risk factors such as dyslipidaemias and reduced glucose tolerance. It is well known that thiazide diuretics and β-blockers have potentially adverse effects on lipid and glucose metabolism, that calcium antagonists and ACE-inhibitors are lipid neutral and that α-blockers have potentially favourable effects. Although the real impact of some of these changes is unproven, it is possible that one or more of the metabolic side effects of drugs such as diuretics and β-blockers may offset some of the benefits of reduced blood pressure. Extensive testing of antihypertensive drugs with a favourable profile can be foreseen in the 1990s.

UR - http://www.scopus.com/inward/record.url?scp=0025690691&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025690691&partnerID=8YFLogxK

U2 - 10.2165/00003495-199000404-00027

DO - 10.2165/00003495-199000404-00027

M3 - Article

C2 - 2151185

AN - SCOPUS:0025690691

VL - 40

SP - 85

EP - 91

JO - Drugs

JF - Drugs

SN - 0012-6667

IS - 4

ER -